Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objectives: To identify post-treatment prognostic factors for medication-related osteonecrosis of the jaw (MRONJ). Materials and Methods: We evaluated 54 MRONJ patients who visited the Department of Dentistry, Ajou University Hospital, from May 2007 to March 2014. Twenty-one patients were surgically managed with debridement or sequestrectomy and 33 patients were conservatively managed using antibiotics. Correlations of age, sex, stage, bisphosphonate duration and type, and drug holiday with the prognosis of MRONJ were investigated. Correlations were verified by logistic regression analysis and t-tests with a significance level of 0.05. Results: Clinical outcomes were evaluated on the basis of both clinical and radiographic findings. Twelve out of 21 surgically managed patients showed a favorable prognosis and nine patients relapsed. Thirty-one of the 33 conservatively managed patients showed no specific change in prognosis, and two patients worsened. Statistical analyses of the conservative management group did not reveal any correlation of the above factors with the prognosis of conservative management. Drug holiday was the only prognostic factor in the surgical management group (P=0.031 in logistic regression analysis, P=0.004 in t-test). Conclusion: Drug holiday is a prognostic factor in the surgical management of MRONJ. Because the drug holiday in the patients of the poor prognosis group occurred 1.5 to 4 months prior to surgical management, we recommend a drug holiday more than 4 months before surgery.
Abstract
Objectives: To identify post-treatment prognostic factors for medication-related osteonecrosis of the jaw (MRONJ). Materials and Methods: We evaluated 54 MRONJ patients who visited the Department of Dentistry, Ajou University Hospital, from May 2007 to March 2014. Twenty-one patients were surgically managed with debridement or sequestrectomy and 33 patients were conservatively managed using antibiotics. Correlations of age, sex, stage, bisphosphonate duration and type, and drug holiday with the prognosis of MRONJ were investigated. Correlations were verified by logistic regression analysis and t-tests with a significance level of 0.05. Results: Clinical outcomes were evaluated on the basis of both clinical and radiographic findings. Twelve out of 21 surgically managed patients showed a favorable prognosis and nine patients relapsed. Thirty-one of the 33 conservatively managed patients showed no specific change in prognosis, and two patients worsened. Statistical analyses of the conservative management group did not reveal any correlation of the above factors with the prognosis of conservative management. Drug holiday was the only prognostic factor in the surgical management group (P=0.031 in logistic regression analysis, P=0.004 in t-test). Conclusion: Drug holiday is a prognostic factor in the surgical management of MRONJ. Because the drug holiday in the patients of the poor prognosis group occurred 1.5 to 4 months prior to surgical management, we recommend a drug holiday more than 4 months before surgery.
참고문헌 (18)
- Devogelaer JP, "Treatment of bone diseases with bisphosphonates, excluding osteoporosis", Curr Opin Rheumatol, 12, pp.331~335 (2000)
- "Medication-related osteonecrosis of the Jaw--2014 update"[URL]
- Marx RE, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
- Mavrokokki T, "Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia", J Oral Maxillofac Surg, 65, pp.415~423 (2007)
- Khosla S, "American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 22, pp.1479~1491 (2007)
- 이정근, "Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report", 대한구강악안면외과학회지, 39(1), pp.9~13 (2013), 대한구강악안면외과학회
- 대한내분비학회, "비스포스포네이트와 관련한 악골(턱뼈) 괴사", Endocrinology and Metabolism, 24(4), pp.227~230 (2009), 대한내분비학회
- Bilezikian JP, "Osteonecrosis of the jaw--do bisphosphonates pose a risk?", N Engl J Med, 355, pp.2278~2281 (2006)
- 박용재, "골다공증을 동반한 류마티스 관절염 환자에서비스포스포네이트 복용 중 발생한 하악골 무혈관골괴사 1예", 대한류마티스학회지, 13(4), pp.150~154 (2006), 대한류마티스학회
- Carlson ER, "Management of antiresorptive osteonecrosis of the jaws with primary surgical resection", J Oral Maxillofac Surg, 72, pp.655~657 (2014)
- Thumbigere-Math V, "Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients.", J Oral Maxillofac Surg, 67, pp.1904~1913 (2009)
- Ruggiero SL, "Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102, pp.433~441 (2006)
- 이호경, "비스포스포네이트 관련 악골괴사(BRONJ)의 병기 2기에서의 외과적, 보존적 치료에 대한 비교 연구", Maxillofacial Plastic Reconstructive Surgery, 35(5), pp.302~309 (2013), 대한악안면성형재건외과학회
- Stockmann P, "The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months", Clin Oral Investig, 18, pp.1299~1304 (2014)
- Holzinger D, "Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs)", Oral Oncol, 49, pp.66~70 (2013)
- Graziani F, "Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases", J Oral Maxillofac Surg, 70, pp.2501~2507 (2012)
- Mücke T, "Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws", J Cancer Res Clin Oncol, 137, pp.907~913 (2011)
- Black DM, "FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial", JAMA, 296, pp.2927~2938 (2006)